-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

Benzinga·09/25/2026 11:50:01
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.